INSMED INCORPORATED

Insmed Incorporated is a biopharmaceutical company specializing in the research, development, and commercialization of drugs used to treat metabolic diseases and serious endocrine disorders. The company's products belong to 3 therapeutic areas: respiratory diseases, immunological and inflammatory diseases, and neurological and rare diseases. At the end of 2025, Insmed Incorporated had two products on the market in the respiratory diseases category: - ARIKAYCE® (71.5% of net sales): used to treat pulmonary infection caused by the Mycobacterium avium complex; and - BRINSUPRI® (28.5%): used to treat bronchiectasis (enlargement of the bronchi) not associated with cystic fibrosis. The United States accounts for 74.7% of net sales. Employees 1,664 Sector Biotechnology & Medical Research